Brunel University Research Archive (BURA) >
Schools >
School of Health Sciences and Social Care >
School of Health Sciences and Social Care Research Papers >

Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/4681

Title: Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials
Authors: Pathan, AA
Sander, CR
Fletcher, HA
Poulton, I
Alder, NC
Beveridge, NER
Whelan, KT
Hill, AVS
McShane, H
Publication Date: 2007
Publisher: Public Library of Science
Citation: PLoS ONE 2(10): e1052
Abstract: Objectives. To investigate the safety and immunogenicity of boosting BCG with modified vaccinia Ankara expressing antigen 85A (MVA85A), shortly after BCG vaccination, and to compare this first with the immunogenicity of BCG vaccination alone and second with a previous clinical trial where MVA85A was administered more than 10 years after BCG vaccination. Design. There are two clinical trials reported here: a Phase I observational trial with MVA85A; and a Phase IV observational trial with BCG. These clinical trials were all conducted in the UK in healthy, HIV negative, BCG naı¨ve adults. Subjects were vaccinated with BCG alone; or BCG and then subsequently boosted with MVA85A four weeks later (short interval). The outcome measures, safety and immunogenicity, were monitored for six months. The immunogenicity results from this short interval BCG prime–MVA85A boost trial were compared first with the BCG alone trial and second with a previous clinical trial where MVA85A vaccination was administered many years after vaccination with BCG. Results. MVA85A was safe and highly immunogenic when administered to subjects who had recently received BCG vaccination. When the short interval trial data presented here were compared with the previous long interval trial data, there were no significant differences in the magnitude of immune responses generated when MVA85A was administered shortly after, or many years after BCG vaccination. Conclusions. The clinical trial data presented here provides further evidence of the ability of MVA85A to boost BCG primed immune responses. This boosting potential is not influenced by the time interval between prior BCG vaccination and boosting with MVA85A. These findings have important implications for the design of efficacy trials with MVA85A. Boosting BCG induced anti-mycobacterial immunity in either infancy or adolescence are both potential applications for this vaccine, given the immunological data presented here. Trial Registration. ClinicalTrials.
Sponsorship: Oxford University was the sponsor for all the clinical trials reported here.
URI: http://bura.brunel.ac.uk/handle/2438/4681
DOI: http://dx.doi.org/10.1371/journal.pone.0001052
ISSN: 1932-6203
Appears in Collections:School of Health Sciences and Social Care Research Papers
Biological Sciences

Files in This Item:

File Description SizeFormat
Fulltext.pdf355.9 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.

 


Library (c) Brunel University.    Powered By: DSpace
Send us your
Feedback. Last Updated: September 14, 2010.
Managed by:
Hassan Bhuiyan